Categories Earnings, Health Care

Bio-Path’s stock tanks as company delivers loss for Q1

Bio-Path Holdings Inc.’s (NASDAQ: BPTH) shares were down 3.2% in morning hours on Thursday after the company reported its first quarter 2019 earnings results.

The bio-tech company reported a net loss of $1.5 million, or $0.89 per share, for the quarter compared to a loss of $1.9 million, or $3.38 per share, in the prior-year period.

R&D expenses decreased to $0.4 million from $0.9 million in the prior-year period, mainly due to lower clinical trial expenses as the operations between Stage 1 and Stage 2 of the Phase 2 clinical trial in AML were modified to include venetoclax combination treatment with prexigebersen.

In April, Bio-Path presented data from preclinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer and acute myelogenous leukemia at the American Association for Cancer Research (AACR) Annual Meeting.

The company anticipates the completion of the Investigational New Drug-enabling studies in 2019 through early 2020, and the filing of an IND application for a Phase 1 study of BP1003 for the treatment of pancreatic cancer in 2020.

In March 2019, Bio-Path issued 712,910 shares of its common stock at a price of $25.95 per share, for gross proceeds of approx. $18.5 million in one transaction. The company also completed two other smaller offerings during the first quarter.

As of March 31, 2019, Bio-Path had cash of $19.3 million, compared to $1 million at December 31, 2018. Bio-Path has not generated significant revenues to date. According to its SEC filings, the company’s ability to generate revenues will depend heavily on the successful development and eventual commercialization of its drug candidates.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

What to look for when Hormel Foods (HRL) reports Q4 2023 earnings

Shares of Hormel Foods Corporation (NYSE: HRL) were down over 1% on Monday. The stock has dropped 29% year-to-date. The food company is set to report its fourth quarter 2023 earnings

Kroger set to report Q3 results. Here’s everything you need to know

The Kroger Co. (NYSE: KR), a leading grocery retailer that operates both in-store and online, will be reporting earnings this week. The company, which is preparing to acquire rival retailer

Earnings Preview: Salesforce will likely deliver another strong quarter

Salesforce, Inc. (NYSE: CRM) achieved accelerated sales growth and profitability in recent quarters, in line with its transformation goal. The customer relationship management platform bets on new opportunities in generative

Comments

  1. Pingback: Hardness Tester
  2. Pingback: ??????? ???????
  3. Pingback: fue
  4. Pingback: Higher education
  5. Pingback: البحث
  6. Pingback: Computer Science
  7. Pingback: IT Careers
  8. Pingback: Tahya Misr Fund
  9. Pingback: dalle caoutchouc
  10. Pingback: Fiverr Earn
  11. Pingback: Fiverr Earn
  12. Pingback: Fiverr Earn
  13. Pingback: fiverrearn.com
  14. Pingback: fiverrearn.com
  15. Pingback: redboost mediprime
  16. Pingback: fiverrearn.com
  17. Pingback: clima
  18. Pingback: clima de hoy
  19. Pingback: fiverrearn.com
  20. Pingback: french bulldog
  21. Pingback: fiverrearn.com
  22. Pingback: fiverrearn.com
  23. Pingback: grey frenchie
  24. Pingback: cavapoo
  25. Pingback: french bulldog
  26. Pingback: viet travel tour
  27. Pingback: future university
  28. Pingback: future university
  29. Pingback: future university
  30. Pingback: houston frenchies
  31. Pingback: Fiverr.Com
  32. Pingback: Fiverr
  33. Pingback: Fiverr
  34. Pingback: grey bulldog
  35. Pingback: future university
  36. Pingback: lean six sigma
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top